Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV
Background & Aims: Accurate HDV RNA quantification is crucial for diagnosis and management of chronic hepatitis delta (CHD), yet a significant variability between assays exists. We compared three methods to quantify HDV RNA levels in untreated and bulevirtide (BLV)-treated patients with CHD....
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | JHEP Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589555924003033 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850025496302059520 |
|---|---|
| author | Maria Paola Anolli Sara Uceda Renteria Elisabetta Degasperi Floriana Facchetti Dana Sambarino Marta Borghi Riccardo Perbellini Roberta Soffredini Sara Monico Annapaola Callegaro Pietro Lampertico |
| author_facet | Maria Paola Anolli Sara Uceda Renteria Elisabetta Degasperi Floriana Facchetti Dana Sambarino Marta Borghi Riccardo Perbellini Roberta Soffredini Sara Monico Annapaola Callegaro Pietro Lampertico |
| author_sort | Maria Paola Anolli |
| collection | DOAJ |
| description | Background & Aims: Accurate HDV RNA quantification is crucial for diagnosis and management of chronic hepatitis delta (CHD), yet a significant variability between assays exists. We compared three methods to quantify HDV RNA levels in untreated and bulevirtide (BLV)-treated patients with CHD. Methods: Frozen plasma from untreated and BLV-treated patients with CHD were tested in a single-center retrospective study using three different assays: Robogene 2.0 HDV RNA Quantification Kit 2.0 (Roboscreen GmbH; limit of detection [LOD] 6 IU/ml on 7500 Fast Real-Time PCR System [Applied Biosystem]), EurobioPlex HDV PCR quantitative kit (Eurobio Scientific; LOD 100 IU/m) on CFX96™ real-time PCR detection system [Bio-Rad]), and AltoStar HDV RT-PCR RUO Kit 1.5 (Altona Diagnostics; estimated LOD <10 IU/ml) on the AltoStar®AM16. Results: Overall, 431 plasma samples from 130 patients with CHD (69 untreated and 61 BLV-treated) were studied. Compared with Robogene 2.0, EurobioPlex reported higher HDV RNA levels (3.78 [0.70–7.99] vs. 4.69 [2.00–8.19] log IU/ml, p <0.0001), with viremia higher than >0.5 log in 160 (69%). Likewise, HDV RNA levels were higher with AltoStar than with Robogene 2.0 (3.32 [0.70–7.37] vs. 3.91 [0.19–7.54] log IU/ml, p <0.0001), with AltoStar reporting HDV RNA levels >0.5 log in 127 (52%). Although virological response rates (≥2 log decline vs. baseline) at Weeks 24 (Robogene 2.0 vs. EurobioPlex and AltoStar) and 48 (Robogene 2.0 vs. AltoStar) were similar across assays, rates of HDV RNA undetectability significantly differed between the three assays at Weeks 24 and 72 (p = 0.003 and p = 0.02, respectively). Conclusions: HDV RNA levels quantified by EurobioPlex and AltoStar were 1 and 0.5 logs higher than those quantified by Robogene 2.0, respectively. HDV RNA undetectability rates during BLV treatment were assay-dependent. Impact and implications:: Management and diagnosis of chronic hepatitis delta (CHD) require standardized tests for HDV RNA quantification. Quantification of HDV RNA is significantly influenced by the quantification method, with EurobioPlex detecting approximatively 1 log and AltoStar 0.5 log IU/ml more than Robogene 2.0, respectively. The HDV RNA undetectability rates during BLV monotherapy significantly differed among assays. These findings are of clinical relevance as patients who achieve negative viremia during BLV monotherapy might be entitled to stop therapy successfully. |
| format | Article |
| id | doaj-art-267dc066f04349fda3e810f893a58c6e |
| institution | DOAJ |
| issn | 2589-5559 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JHEP Reports |
| spelling | doaj-art-267dc066f04349fda3e810f893a58c6e2025-08-20T03:00:50ZengElsevierJHEP Reports2589-55592025-03-017310129910.1016/j.jhepr.2024.101299Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDVMaria Paola Anolli0Sara Uceda Renteria1Elisabetta Degasperi2Floriana Facchetti3Dana Sambarino4Marta Borghi5Riccardo Perbellini6Roberta Soffredini7Sara Monico8Annapaola Callegaro9Pietro Lampertico10Division of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; D-SOLVE Consortium, an EU Horizon Europe Funded Project (No. 101057917), Hannover, GermanyMicrobiology and Virology Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDivision of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; D-SOLVE Consortium, an EU Horizon Europe Funded Project (No. 101057917), Hannover, GermanyDivision of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDivision of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDivision of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDivision of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDivision of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDivision of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyMicrobiology and Virology Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, ItalyDivision of Gastroenterology and Hepatology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; D-SOLVE Consortium, an EU Horizon Europe Funded Project (No. 101057917), Hannover, Germany; Department of Pathophysiology and Transplantation, CRC “A. M. and A. Migliavacca” Center for Liver Disease, University of Milan, Milan, Italy; Corresponding author. Address: Division of Gastroenterology and Hepatology; Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico; Via F. Sforza 35, 20122 Milan, Italy. Tel.: +39-0255035432.Background & Aims: Accurate HDV RNA quantification is crucial for diagnosis and management of chronic hepatitis delta (CHD), yet a significant variability between assays exists. We compared three methods to quantify HDV RNA levels in untreated and bulevirtide (BLV)-treated patients with CHD. Methods: Frozen plasma from untreated and BLV-treated patients with CHD were tested in a single-center retrospective study using three different assays: Robogene 2.0 HDV RNA Quantification Kit 2.0 (Roboscreen GmbH; limit of detection [LOD] 6 IU/ml on 7500 Fast Real-Time PCR System [Applied Biosystem]), EurobioPlex HDV PCR quantitative kit (Eurobio Scientific; LOD 100 IU/m) on CFX96™ real-time PCR detection system [Bio-Rad]), and AltoStar HDV RT-PCR RUO Kit 1.5 (Altona Diagnostics; estimated LOD <10 IU/ml) on the AltoStar®AM16. Results: Overall, 431 plasma samples from 130 patients with CHD (69 untreated and 61 BLV-treated) were studied. Compared with Robogene 2.0, EurobioPlex reported higher HDV RNA levels (3.78 [0.70–7.99] vs. 4.69 [2.00–8.19] log IU/ml, p <0.0001), with viremia higher than >0.5 log in 160 (69%). Likewise, HDV RNA levels were higher with AltoStar than with Robogene 2.0 (3.32 [0.70–7.37] vs. 3.91 [0.19–7.54] log IU/ml, p <0.0001), with AltoStar reporting HDV RNA levels >0.5 log in 127 (52%). Although virological response rates (≥2 log decline vs. baseline) at Weeks 24 (Robogene 2.0 vs. EurobioPlex and AltoStar) and 48 (Robogene 2.0 vs. AltoStar) were similar across assays, rates of HDV RNA undetectability significantly differed between the three assays at Weeks 24 and 72 (p = 0.003 and p = 0.02, respectively). Conclusions: HDV RNA levels quantified by EurobioPlex and AltoStar were 1 and 0.5 logs higher than those quantified by Robogene 2.0, respectively. HDV RNA undetectability rates during BLV treatment were assay-dependent. Impact and implications:: Management and diagnosis of chronic hepatitis delta (CHD) require standardized tests for HDV RNA quantification. Quantification of HDV RNA is significantly influenced by the quantification method, with EurobioPlex detecting approximatively 1 log and AltoStar 0.5 log IU/ml more than Robogene 2.0, respectively. The HDV RNA undetectability rates during BLV monotherapy significantly differed among assays. These findings are of clinical relevance as patients who achieve negative viremia during BLV monotherapy might be entitled to stop therapy successfully.http://www.sciencedirect.com/science/article/pii/S2589555924003033HDVHDV RNAPCRChronic hepatitis deltaNucleic acidBulevirtide |
| spellingShingle | Maria Paola Anolli Sara Uceda Renteria Elisabetta Degasperi Floriana Facchetti Dana Sambarino Marta Borghi Riccardo Perbellini Roberta Soffredini Sara Monico Annapaola Callegaro Pietro Lampertico Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV JHEP Reports HDV HDV RNA PCR Chronic hepatitis delta Nucleic acid Bulevirtide |
| title | Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV |
| title_full | Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV |
| title_fullStr | Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV |
| title_full_unstemmed | Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV |
| title_short | Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV |
| title_sort | comparing methods for plasma hdv rna quantification in bulevirtide treated and untreated patients with hdv |
| topic | HDV HDV RNA PCR Chronic hepatitis delta Nucleic acid Bulevirtide |
| url | http://www.sciencedirect.com/science/article/pii/S2589555924003033 |
| work_keys_str_mv | AT mariapaolaanolli comparingmethodsforplasmahdvrnaquantificationinbulevirtidetreatedanduntreatedpatientswithhdv AT saraucedarenteria comparingmethodsforplasmahdvrnaquantificationinbulevirtidetreatedanduntreatedpatientswithhdv AT elisabettadegasperi comparingmethodsforplasmahdvrnaquantificationinbulevirtidetreatedanduntreatedpatientswithhdv AT florianafacchetti comparingmethodsforplasmahdvrnaquantificationinbulevirtidetreatedanduntreatedpatientswithhdv AT danasambarino comparingmethodsforplasmahdvrnaquantificationinbulevirtidetreatedanduntreatedpatientswithhdv AT martaborghi comparingmethodsforplasmahdvrnaquantificationinbulevirtidetreatedanduntreatedpatientswithhdv AT riccardoperbellini comparingmethodsforplasmahdvrnaquantificationinbulevirtidetreatedanduntreatedpatientswithhdv AT robertasoffredini comparingmethodsforplasmahdvrnaquantificationinbulevirtidetreatedanduntreatedpatientswithhdv AT saramonico comparingmethodsforplasmahdvrnaquantificationinbulevirtidetreatedanduntreatedpatientswithhdv AT annapaolacallegaro comparingmethodsforplasmahdvrnaquantificationinbulevirtidetreatedanduntreatedpatientswithhdv AT pietrolampertico comparingmethodsforplasmahdvrnaquantificationinbulevirtidetreatedanduntreatedpatientswithhdv |